These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2481779)

  • 21. Antiarrhythmic plasma concentrations of mexiletine on canine ventricular arrhythmias.
    Hashimoto K; Ishii M; Komori S
    J Cardiovasc Pharmacol; 1984; 6(2):213-9. PubMed ID: 6200706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a new antiarrhythmic drug TYB-3823 on canine ventricular arrhythmia models.
    Hashimoto K; Sugiyama A; Haruno A; Matsuzaki T; Hirasawa A
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):336-42. PubMed ID: 1709241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog.
    Haruno A; Hashimoto K
    Jpn J Pharmacol; 1995 May; 68(1):95-102. PubMed ID: 7494388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective plasma concentrations of antiarrhythmic drugs against sustained halothane-adrenaline arrhythmia in dogs.
    Shibuya T; Hashimoto K; Imai S
    J Cardiovasc Pharmacol; 1983; 5(4):538-45. PubMed ID: 6193348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiarrhythmic effects of a novel class III drug, KCB-328, on canine ventricular arrhythmia models.
    Xue Y; Tanabe S; Nabuchi Y; Hashimoto K
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):239-47. PubMed ID: 9700986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Actions of a newly synthesized compound (711389-S) on various types of experimentally induced arrhythmias in mammalian species in situ.
    Kadowaki Y; Ohta T; Hotokebuchi N; Kimoto S; Haruna M; Nakao T; Ueda M; Nishi K
    Jpn J Pharmacol; 1988 Apr; 46(4):359-72. PubMed ID: 3404766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia.
    Hashimoto K; Satoh H; Shibuya T; Imai S
    J Pharmacol Exp Ther; 1982 Dec; 223(3):801-10. PubMed ID: 7143241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of a new antiarrhythmic drug, KW-3407, on canine ventricular arrhythmia models].
    Wu Z; Awaji T; Motomura S; Hashimoto K
    Nihon Yakurigaku Zasshi; 1992 Aug; 100(2):117-26. PubMed ID: 1427497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of antiarrhythmic drugs on canine ventricular arrhythmia models].
    Hashimoto K
    Nihon Yakurigaku Zasshi; 1989 Feb; 93(2):29-39. PubMed ID: 2656435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of a new class I antiarrhythmic drug bidisomide on canine ventricular arrhythmia models.
    Zhenjiu W; Awaji T; Hirasawa A; Motomura S; Hashimoto K
    Mol Cell Biochem; 1993 Feb; 119(1-2):159-69. PubMed ID: 8455577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiarrhythmic effects of an aconitine-like compound, TJN-505, on canine arrhythmia models.
    Arita J; Xue YX; Aye NN; Fukuyama K; Wakui Y; Niitsu K; Maruno M; Siying C; Hashimoto K
    Eur J Pharmacol; 1996 Dec; 318(2-3):333-40. PubMed ID: 9016923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models.
    Takahara A; Hirasawa A; Dohmoto H; Shoji M; Yoshimoto R; Sugiyama A; Hashimoto K
    Jpn J Pharmacol; 2001 Sep; 87(1):21-6. PubMed ID: 11676194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of betaxolol, a new beta 1 selective blocker, on canine ventricular arrhythmias.
    Mitsuhashi H; Akiyama K; Hashimoto K
    Jpn J Pharmacol; 1987 Feb; 43(2):179-85. PubMed ID: 2883336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiarrhythmic effects of coronary vasodilators on canine ventricular arrhythmia models.
    Komori S; Ishii M; Hashimoto K
    Jpn J Pharmacol; 1985 May; 38(1):73-82. PubMed ID: 4021230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-(2,6-Dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165): a new potent and long-acting antiarrhythmic agent.
    Aisaka K; Hidaka T; Inomata N; Hamasaki S; Ishihara T; Morita M
    Arzneimittelforschung; 1985; 35(8):1239-45. PubMed ID: 4074441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 4th communication: influence on experimentally induced ventricular arrhythmia in dogs.
    Yoshimura A; Yoshioka K; Hino M; Sugawara H; Sakato M; Endoh M
    Arzneimittelforschung; 1999 May; 49(5):420-6. PubMed ID: 10367104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness?
    Hashimoto K; Haruno A; Matsuzaki T; Sugiyama A; Akiyama K
    Cardiovasc Drugs Ther; 1991 Aug; 5 Suppl 4():805-17. PubMed ID: 1657110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiarrhythmic and cardiohemodynamic effects of a novel Ca(2+) channel blocker, AH-1058, assessed in canine arrhythmia models.
    Takahara A; Sugiyama A; Dohmoto H; Yoshimoto R; Hashimoto K
    Eur J Pharmacol; 2000 Jun; 398(1):107-12. PubMed ID: 10856454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of the electrophysiological and antiarrhythmic properties of the N-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog.
    Bagwell EE; Walle T; Drayer DE; Reidenbert MM; Pruett JK
    J Pharmacol Exp Ther; 1976 Apr; 197(1):38-48. PubMed ID: 1263131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and plasma concentrations of SC-36602 in canine models of ventricular arrhythmia.
    Garthwaite SM; Hatley FR; Frederick LG; Cook C
    J Cardiovasc Pharmacol; 1989 Feb; 13(2):218-26. PubMed ID: 2468949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.